Health and Human Services Logo

  U.S. Department of Health and Human Services | National Institutes of Health

Biologics Regulation and ResearchThe People and Work of Buildings 29 & 29A

Versions Compared

Old Version 47

changes.mady.by.user Katie Watts

Saved on

compared with

New Version 48

changes.mady.by.user Katie Watts

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Dive
preface
classgrid-row grid-gap
Dive
classgrid-col-8

Dr. Ruth Kirschstein was the first woman at the National Institutes of Health (NIH) to head an institute (the National Institute of General Medical Sciences [NIGMS]) and the first woman to serve as Acting Director of the NIH (in 1993 and again in 2000).

Ruth Kirschstein was born in Brooklyn, New York in 1926. Her father’s family immigrated from a village near the borders of Poland and Russia when he was eight years old. Her father grew up to become a chemist who inspired in her an interest in science and a love of music. Her mother was a public school teacher. Dr. Ruth Kirschstein received her B.A. magna cum laude from Long Island University in 1947 and her M.D. from Tulane University School of Medicine in 1951. 

Dr. Kirschstein came to the NIH in 1955 with her husband, pathologist Dr. Al Rabson. She researched cancer viruses early in her career and then live-virus vaccines for polio, measles, and rubella. In 1955, the year following a field trial that showed the Jonas Salk inactivated (killed) polio vaccine to be safe and effective, the NIH Division of Biologics Standards (DBS) licensed several firms to produce the vaccine. Cutter Laboratories accidentally released vaccine that retained live polio virus, resulting in 260 paralytic cases of the disease, a disaster that caused panic among parents and scientists alike.

In the following years, Dr. Kirschstein’s polio investigations paved the way for safer vaccines, both the killed vaccine and live, attenuated oral polio vaccine.  She and her colleagues shed light on the pathogenesis of the polio virus and developed a standardized test involving precise, experimental inoculation of vaccine matter. It served as the basis for the testing DBS conducted on every lot of polio vaccine produced and the laboratory instructed vaccine producers manufactured as well as for the laboratories that produced the vaccine and others that needed to know the procedure from around the world.

Dive
classgrid-col-4

Professional photo of Dr. Ruth Kirschstein with curled hair wearing a pearl necklace and a collared shirt

Span
classcaption

Dr. Ruth Kirschstein 

Span
classcredit

National Library of Medicine 

Three scientists in a laboratory looking at bottles of solution. The man on the left is holding up a bottle, a woman and a man are seated to the right. All are wearing white lab coats.

Span
classcaption

Dr. Samuel Baron (left), Dr. Ruth Kirschstein (center), and unidentified man (right). 

Span
classcredit

Office of NIH History & Stetten Museum

An authority on infectious neuropathology of monkeys, she received the Department of Health, Education, and Welfare (DHEW) Superior Service Award in 1971 for her contributions in developing monkey safety tests to live viral vaccines and for research on viral oncogenesis.

Dr. Kirschstein became chief Chief of the Division of Biologics Standards (DBS) Laboratory of Pathology in 1961. She was promoted to assistant director Assistant Director of the Division of Biologics Standards in 1972. When DBS moved administratively to the Food and Drug Administration (FDA), Dr. Kirschstein became the deputy director Deputy Director of what then became called the FDA Bureau of Biologics.

From 1974 until 1993, she was the Director of the National Institute of General Medical Sciences (NIGMS). As Director of NIGMS, she worked tirelessly to expand the ranks of women and minorities in science at NIH and elsewhere. She did so likely in response to the discrimination she had experienced as a female scientist. She was one of ten women in her medical school class of 110 at Tulane. When she was a pathologist at the NIH, she had to fight for her promotions, being turned down twice for a promotion to the GS-15 rank/salary. Because she was a married woman, the men in administrative roles didn’t feel that she needed the raise since her husband also worked. Dr. Kirschstein did not give up and received the promotion on her third try. She also fought for promotions for her minority lab technicians like George Rusten. Dr. Kirschstein was a champion of minorities in the sciences throughout her career , but especially when she led NIGMS. She received an award from the Association of Minority Health Professions Schools in 1988 at a ceremony in Atlanta, Georgia. She also received the Geraldine P. Woods Award in 2002 that acknowledged her leadership, dedication, and commitment to the research training of minorities while at the head of NIGMS and NIH.

...

In January 2000, she once again became Acting Director. Dr. Varmus had left NIH to become the president and CEO of Memorial Sloan-Kettering Cancer Center in New York City. This time, Dr. Kirschstein was Acting Director from 2000 to 2002, a period where she had the opportunity to showcase many scientific and public health achievements at NIH. In March 2000, the NIH launched the first phase of a consumer friendly database, www.ClinicalTrials.gov where people could research thousands of medical studies. The Human Genome Project led by Dr. Francis Collins had produced a working draft of the DNA sequence of the human genome by June 2000. The Office of Research on Minority Health hosted a conference in 2000 where Dr. Kirschstein made a renewed call for the value and need of diversity in science. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) was established in 2000 as well, the 27th independent component of the NIH. 2001 would prove a more difficult year for Dr. Kirschstein as Acting Director. President George W. Bush, early in his first term, announced that Federal funds could be used to support stem cell research but only using those existing lines of human embryonic stem cells, and they had to meet certain criteria. The process of identifying existing stem cells was a long and tedious process, and as Acting Director, Dr. Kirschstein had the task of explaining the news to the scientific community. And then Then the terrorist attacks of September 11, 2001 , happened. Dr. Kirschstein would oversee the establishment of a variety of security measures such as the installation of the Bethesda campus perimeter fence, enforcement of wearing ID badges, and a new surge in funding of counterterrorism research. From 2002 to 2009, Dr. Kirschstein served as a senior advisor to the NIH Director and during those years also served as the interim director of the Center for Complementary and Alternative Medicine (NCCAM).

...
Return to top